Features
In conversation with
-
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.
-
How LSD and classic psychedelics are re-entering modern psychiatry
Definium’s CMO talks about evaluating psychedelic medicine(s) in the modern era and developing novel treatments for mental health disorders.
-
How human organs are rewriting the rules of drug development
Dr. Jenna DiRito talks about why human organs may represent the “missing chapter” in our understanding of disease, and how this approach is already changing conversations with investors and regulators.
-
How digital twins are pioneering a new era of personalized, longitudinal healthcare
Dr. Amanda Randles explains how they are developing digital twins to move medicine beyond static snapshots to dynamic, personalized care.
-
Why Pharma can’t ignore friendshoring in supply chain
Bora Pharma exec, J.D. Mowery, discusses how geopolitical shifts are reshaping pharmaceutical manufacturing and supply chain strategy.
-
Inside Immunai’s plan to map the entire immune system
Immunai CEO Noam Solomon details four pivotal studies shaping the future of immunology and oncology research, as part of the ‘Grand Collaboration’.
-
How ambient AI is capturing healthcare’s unheard data
The Sciensus team discusses how ambient AI captures patient sentiment to augment nurses, personalise care, and help keep patients healthier at home.
Analysis
-
CAR T enters a new era of in vivo reprogramming of T cells
Vyriad’s Luke Russell explores the technical and economic promise of in vivo CAR T-cell therapies.
-
Building resilient pharmaceutical supply chains in an era of disruption
Kum Ming Woo advises prioritizing supplier quality & availability over cost, emphasizing geographic diversification and stage-appropriate strategies.
-
Hospital of 2026: Local LLMs and AI Are Redefining Healthcare
myTomorrow’s Danny den Hamer identifies two trends for 2026: hospitals adopting local AI/trusted partners, and a rise in certified AI medical devices.
Archive
-
Arkin Bio Ventures III: $100 million fund for transformative therapies
Fund lead, Dr. Pini Orbach, talks about the fund targeting oncology, immunology, inflammation, rare diseases, and their aim to be an active partner from day one.
-
The New Gold Rush: High-stakes race for multi-cancer blood tests
Abbott’s $23 billion Exact Sciences buyout sets stage for high-stakes MCED battle, Elena Meng talks about the major players in the sector and hurdles.
-
Examining the growing delays in clinical trial start-up
ICON exec discusses the increasing timeframe from site selection to full activation, including the issues contributing to the delay and measures to address them.
-
CAR T enters a new era of in vivo reprogramming of T cells
Vyriad’s Luke Russell explores the technical and economic promise of in vivo CAR T-cell therapies.
-
Building resilient pharmaceutical supply chains in an era of disruption
Kum Ming Woo advises prioritizing supplier quality & availability over cost, emphasizing geographic diversification and stage-appropriate strategies.
-
Hospital of 2026: Local LLMs and AI Are Redefining Healthcare
myTomorrow’s Danny den Hamer identifies two trends for 2026: hospitals adopting local AI/trusted partners, and a rise in certified AI medical devices.
-
Arkin Bio Ventures III: $100 million fund for transformative therapies
Fund lead, Dr. Pini Orbach, talks about the fund targeting oncology, immunology, inflammation, rare diseases, and their aim to be an active partner from day one.
-
The New Gold Rush: High-stakes race for multi-cancer blood tests
Abbott’s $23 billion Exact Sciences buyout sets stage for high-stakes MCED battle, Elena Meng talks about the major players in the sector and hurdles.
-
Examining the growing delays in clinical trial start-up
ICON exec discusses the increasing timeframe from site selection to full activation, including the issues contributing to the delay and measures to address them.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Old becomes New: CNS Pharma’s quest to tackle brain cancers
CNS Pharmaceuticals’ CMO explains how they are re-engineering old chemotherapies to penetrate the brain, aiming for a breakthrough in treating aggressive glioblastoma.
-
Secura Bio’s Copiktra PTCL data shines at ASH 2025
The company’s exec talks about how new analyses bolster the case for Copiktra in tough-to-treat lymphomas, informing a pivotal Phase III trial strategy.
-
CTMC maps out plans to democratize cell therapy
CTMC’s Amy Hay details a partnership model to share knowledge and expand cell therapy access worldwide, starting with Brazil.